SYNTHROID 137 MCG
LEVOTHYROXINE SODIUM : 137 MCG · DIN 02233852 · BGP PHARMA ULC
Health Canada status: MARKETED
What is SYNTHROID?
SYNTHROID 137 MCG contains LEVOTHYROXINE SODIUM : 137 MCG. It is listed in the Health Canada Drug Product Database under DIN 02233852, held by BGP PHARMA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 10-Mar-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SYNTHROID used for?
Replacement/supplemental therapy for hypothyroidism (primary, secondary, tertiary); pituitary TSH suppression for well-differentiated papillary or follicular thyroid carcinoma.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is SYNTHROID called?
The same molecule, LEVOTHYROXINE SODIUM, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Eltroxin | Latin | Australia |
| APO-Levothyroxine | Latin | Australia |
| Eutroxsig | Latin | Australia |
| Levothox | Latin | Australia |
| Levothyroxine Lup | Latin | Australia |
| Levothyroxine Sandoz | Latin | Australia |
| LEVOXINE | Latin | Australia |
| Oroxine | Latin | Australia |
| Thyrox | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02233852 |
|---|---|
| Brand name | SYNTHROID |
| Generic / active ingredient | LEVOTHYROXINE SODIUM : 137 MCG |
| Manufacturer | BGP PHARMA ULC |
| Strength | 137 MCG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | H03AA01 LEVOTHYROXINE SODIUM |
| AHFS class | 84:80.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Mar-2016 |
| Original market date | 1998-05-04 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02233852 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2233852 |
| Brand name | SYNTHROID |
| Active ingredient / INN | LEVOTHYROXINE SODIUM : 137 MCG |
| ATC code | H03AA01 |
| ATC anatomical main group | H — Systemic hormonal preparations |
| ATC therapeutic subgroup | H03 |
| AHFS class | 84:80.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | BGP PHARMA ULC |
How is it administered?
Administer once daily on empty stomach, 0.5-1 hour before breakfast. Individualize dose based on TSH/T4 levels. Usual adult dose ~1.7 mcg/kg/day. Titrate in 12.5-25 mcg increments.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text sections (refer to section 11 in full monograph).
How is it supplied?
Bottles of 90 and 1000 tablets (300 mcg strength available in bottles of 90 only).
Which pack is which?
| Strength on the label | 137 MCG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | Bottles of 90 and 1000 tablets (300 mcg strength available in bottles of 90 only). |
| Storage | Not explicitly detailed in the provided text sections (refer to section 11 in full monograph). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Contraindications
Hypersensitivity; untreated subclinical or overt thyrotoxicosis; acute MI, myocarditis, or pancarditis; uncorrected adrenal insufficiency; pregnant women treated with anti-thyroid drugs.
Warnings and precautions
Not for obesity/weight loss (Serious Warning). Narrow therapeutic index. Exercise caution in patients with cardiovascular disorders. Monitor for iatrogenic hyperthyroidism.
Is LEVOTHYROXINE SODIUM in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 24 Apr 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code H03AA01 LEVOTHYROXINE SODIUM. 33 of 109 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LEVOTHYROXINE | 100 MCG | TABLET | APOTEX INC | MARKETED | DIN 02534681 |
| APO-LEVOTHYROXINE | 112 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550741 |
| APO-LEVOTHYROXINE | 125 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550768 |
| APO-LEVOTHYROXINE | 137 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550776 |
| APO-LEVOTHYROXINE | 150 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550784 |
| APO-LEVOTHYROXINE | 175 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550792 |
| APO-LEVOTHYROXINE | 200 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550806 |
| APO-LEVOTHYROXINE | 25 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550709 |
| APO-LEVOTHYROXINE | 300 MCG | TABLET | APOTEX INC | MARKETED | DIN 02534703 |
| APO-LEVOTHYROXINE | 50 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550717 |
Who else supplies LEVOTHYROXINE SODIUM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LEVOTHYROXINE SODIUM appears in 432 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does LEVOTHYROXINE SODIUM cost around the world?
LEVOTHYROXINE SODIUM is listed on 4 national price registers Nexara tracks, across 420 pack listings published on 4 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 12 | 305 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 69 | 69 | 03 Sep 2026 |
| Australia | ex-manufacturer | 9 | 37 | 08 Sep 2026 |
| United Kingdom | hospital | 9 | 9 | 31 Aug 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.